Who Is Dan Karlin? Chief Medical Officer, Definium Therapeutics
Chief Medical Officer of Definium Therapeutics
Dan Karlin, MD, is the Chief Medical Officer of Definium Therapeutics.
At Mind Medicine Law, we track the people building legal, evidence-based access to psychedelic medicine: the companies running the trials, the researchers and advocates behind them, and the officials who write and run the laws.
Karlin holds a medical degree and communicates clinical trial results for DT120, as well as educational initiatives addressing generalized anxiety disorder and pharmaceutical LSD.
Where Dan Karlin Is Now
- Current role: Chief Medical Officer
- Organization: Definium Therapeutics
- Recent news: Sharing Phase 3 data for DT120 Orally Disintegrating Tablet at major psychiatric conferences
Dan Karlin serves as the Chief Medical Officer of Definium Therapeutics, as reported by The Globe and Mail.
Clinical Assessment of DT120
Dan Karlin expressed enthusiasm for sharing new DT120 program data with the psychiatric community at the NEI Fall Congress, noting that presentations add to the growing body of evidence from the clinical development program in generalized anxiety disorder (GAD) and major depressive disorder (MDD) and support continued clinical assessment of DT120's potential role in treating these conditions, as reported by AOL.
Karlin also stated that Definium would present findings from its Phase 3 clinical development program for DT120 Orally Disintegrating Tablet in GAD and MDD at Psych Congress, according to MarketScreener.
Epidemiological Research on Suicidal Ideation
Karlin announced the presentation of new epidemiological research examining suicidal ideation in anxiety, depression, and comorbid populations to better understand suicide risk, as covered by MarketScreener.
In addition, Karlin voiced pride in contributing to research on suicide risk during National Suicide Prevention Awareness Month.
Educational Initiatives and Psychedelic Research
Karlin stated that mental health providers caring for the millions living with GAD deserve more support, explaining that the Wired for Worry initiative equips healthcare providers with emerging science on the neural dysregulation underlying generalized anxiety disorder and can help bolster their clinical toolkit, according to AOL. He noted that a deeper understanding of disease-related information and management tools is essential to advancing knowledge of GAD.
Regarding psychedelics, Karlin asserted that the gap between the impact of psychiatric disorders and the lack of robustly effective treatments creates an urgent need for new scientific approaches, as reported by Nasdaq. He highlighted the importance of methodologically sound clinical studies investigating psychedelics such as LSD for psychological distress, stated that research efforts in the psychedelic renaissance are reshaping understanding of LSD's role in mental health care, and explained that the Rerouting Minds campaign aims to build awareness among clinicians and decision-makers of pharmaceutical LSD's transformative potential.
Frequently asked questions
Who is Dan Karlin?
Dan Karlin, MD, is the Chief Medical Officer of Definium Therapeutics.
What medical degree does Dan Karlin hold?
Dan Karlin holds a medical degree (MD).
What data has Dan Karlin presented regarding DT120?
Dan Karlin announced and presented data from Definium's Phase 3 clinical development program for DT120 Orally Disintegrating Tablet in generalized anxiety disorder (GAD) and major depressive disorder (MDD) at the NEI Fall Congress and Psych Congress.
What is the Wired for Worry initiative according to Dan Karlin?
Karlin stated that the Wired for Worry initiative equips healthcare providers with emerging science on the neural dysregulation underlying generalized anxiety disorder to help bolster their clinical toolkit.
What has Dan Karlin stated about research into LSD?
Karlin highlighted the importance of methodologically sound clinical studies investigating psychedelics such as LSD for psychological distress and stated that the Rerouting Minds campaign aims to build awareness among clinicians and decision-makers regarding pharmaceutical LSD's transformative potential.
What epidemiological research did Dan Karlin announce?
Dan Karlin announced the presentation of new epidemiological research examining suicidal ideation in anxiety, depression, and comorbid populations to improve understanding of suicide risk.
Sources
General information compiled from the public reporting cited above, not medical or legal advice. Mention of a treatment, trial or bill is not a claim that it is safe, effective or legal where you live. Not endorsed by or affiliated with Dan Karlin or Definium Therapeutics. See more people in psychedelic medicine.